Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financi
Johnson & Johnson has reached a deal to acquire Shockwave Medical for around $13.1 billion, expanding its position in medical devices used to treat heart disease.
Biotech giant CSL has seen almost 5% wiped off the value of its shares after one of its most anticipated pipeline products failed a phase 3 trial in heart attack patients.
NICE has set a new target for cholesterol levels in people who have had a heart attack or stroke to reduce the risk of them having another, encouraging the use of addition
Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh